Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MACCO-A: Microarray Analysis in Metastatic Colon Cancer
NCT00127036Phase 2Terminated
- Sponsor
- Moffitt Cancer Center
- Start
- Oct 2003
- Primary completion
- Dec 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab in colorectal cancer (CRC) (2 arms), sponsored by Moffitt Cancer Center. Primary endpoint: Number of Participants Per Treatment Arm, Per Tumor Tissue Response Classifier. Started Oct 2003; status: terminated.
02
Drugs
bevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00127036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00127036.